OPKO Health, Inc. ($OPK) is a healthcare company that provides assistance through diagnostic and pharmaceutical studies. It is currently strongly contributing to COVID-19 testing, having conducted more than 5.2 million diagnostic tests and 331,600 COVID-19 antibody tests. In addition to the activities around COVID-19, Raydalee® and 4Kscore® are two popular and successful tests/products from OPKO.
|Shrooms To Go – Urban Farmers – Should You Buy This Stock|
|Pandemic Play – Dillards Department Store Soars Ahead – Buffett Sniffing Around !|
Raydalee® is a commercialized kidney drug that is eligible for more than $899 million in milestone payments and 10% more royalties from distribution partners. Somatrogon, a major growth hormone replacement therapy, has already proven its superiority in phase 3 clinical trials. By the end of this year, OPKO will file a biological license application with the Food and Drug Administration (FDA) for Somatrogon. It has great potential with an estimated market opportunity of more than $3 billion per year.
4Kscore® test is a unique, recognized blood test to assess the risk of aggressive prostate cancer. It is used in men after an abnormal prostate-specific antigen (PSA) or digital rectal exam (DRE) result. Two prospective clinical studies showed that approximately 1,500 patients demonstrated that the 4Kscore® had 94% sensitivity and 95% negative predictive value for detecting prostate cancer. The 4Kscore® is now used by more than 4,000 urologists from all over the world, which is equivalent to more than 250,000 tests performed.
The test has been included in the National Comprehensive Cancer Network Guidelines® (NCCN) since 2015 and in the European Association of Urology Prostate Cancer Guidelines since 2016.
The Financial Spectrum
OPKO posted a market capitalization of $2.8 billion in the past financial year, with a loss of $315 million and a final annual loss of approximately $200 million. A positive side note here is that the difference between loss and break-even has narrowed. It expects a 12% earnings improvement through 2025. In addition, the company has a four-quarter earnings surprise averaging 43.6%. The company is now expected to make a profit of $30 million by 2020. Based on analyst estimates from previous years, the company is now expected to grow at an annual rate of 29%. A hopeful development that comes with a risk. If the percentage turns out to be too aggressive, the business could be profitable much later.
OPKO has managed its capital well and judiciously, with debt accounting for 18% of equity. What can be concluded from this is that the company mainly financed its activities with equity capital. The low debt obligation therefore reduces the risk associated with investments in the loss-making company. During the second quarter, sales and net income grew to $301.2 million and $33.7 million, respectively, compared to Q2 2019 sales of $226.4 million and a net loss of $59.8 million.
The stock is up a stunning 188.9% over the last six months, compared to an industry growth of 30.6%.
For more information, visit the website: https://www.opko.com/
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.